Literature DB >> 32019759

SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?

Michael Walsh1,2,3.   

Abstract

Keywords:  albuminuria; atrasentan; chronic kidney failure; chronic renal insufficiency; confidence intervals; creatinine; diabetic nephropathies; diabetic nephropathy; endothelin A receptor; endothelin A receptor antagonists; humans; incidence; kidney; nephrology; pyrrolidines; randomized controlled trials; reproducibility of results; sample size; type 2 diabetes mellitus

Year:  2020        PMID： 32019759      PMCID： PMC7274291          DOI： 10.2215/CJN.08540719

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

Review 1.  Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

Authors:  Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay
Journal:  JAMA       Date:  2010-03-24       Impact factor: 56.272

Review 2.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

Authors:  G F M Strippoli; C Bonifati; M Craig; S D Navaneethan; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 3.  The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index.

Authors:  Michael Walsh; Sadeesh K Srinathan; Daniel F McAuley; Marko Mrkobrada; Oren Levine; Christine Ribic; Amber O Molnar; Neil D Dattani; Andrew Burke; Gordon Guyatt; Lehana Thabane; Stephen D Walter; Janice Pogue; P J Devereaux
Journal:  J Clin Epidemiol       Date:  2014-02-05       Impact factor: 6.437

4.  Intravenous streptokinase in acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1986-11-20       Impact factor: 91.245

5.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

6.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Authors:  Hiddo J L Heerspink; Hans-Henrik Parving; Dennis L Andress; George Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John J V McMurray; Joel Z Melnick; Michael G Miller; Pablo E Pergola; Vlado Perkovic; Sheldon Tobe; Tingting Yi; Melissa Wigderson; Dick de Zeeuw
Journal:  Lancet       Date:  2019-04-14       Impact factor: 79.321

7.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

8.  The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study.

Authors:  Kristian Thorlund; Georgina Imberger; Michael Walsh; Rong Chu; Christian Gluud; Jørn Wetterslev; Gordon Guyatt; Philip J Devereaux; Lehana Thabane
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

9.  A perfect correlate does not a surrogate make.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  BMC Med Res Methodol       Date:  2003-09-09       Impact factor: 4.615
  9 in total
  2 in total

1.  Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.

Authors:  Hiddo J L Heerspink; Dick de Zeeuw
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-28       Impact factor: 10.614

Review 2.  Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review.

Authors:  Noorain Ahmad; Harish Veerapalli; Chetan Reddy Lankala; Everardo E Castaneda; Afia Aziz; Amy G Rockferry; Pousette Hamid
Journal:  Cureus       Date:  2021-11-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.